Compare iShares Bitcoin Trust (IBIT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Incyte Corporation — how do they compare? iShares Bitcoin Trust trades at $46.68 (market cap $67.31B), while Incyte Corporation trades at $113.1 (market cap $22.85B). The key difference: iShares Bitcoin Trust is far larger — about 2.9× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Incyte Corporation for 33 Days on average.
| IBIT | INCY | |
|---|---|---|
Market Cap | $67.31B | $22.85B |
Volume | 56,154,544 | 1,927,029 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $129.93 |
52-Week Low | $33.29 | $83.80 |
Typical Hold Time | 40 Days | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal. The stock faces immediate support at $47 and resistance at $48. Recent news highlights significant institutional interest, with BlackRock's IBIT recording $196 million in daily inflows according to 24/7 Wall Street on October 4, 2026.
The outlook remains positive with strong institutional inflows and technical momentum, though the absence of traditional financial metrics requires careful evaluation. Key risks include market volatility and dependency on Bitcoin ETF performance, while analyst sentiment appears cautiously optimistic based on recent fund flow trends.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
